- Trial phase
- Phase 2
- Time to market
- SPY007 is still in preclinical development, and the SPY772 coformulation has not yet entered clinical testing. The Phase 2 SKYLIGHT surrogate trial's topline data is expected in late 2027 or early 2028. If positive, the coformulation would still need to enter and complete clinical trials before any potential approval, putting commercialization several years away.
- Why 3/10
- SPY772 has no hard, dated binary catalyst within the next ~12 months; the next milestone is topline Week 16 data from the Phase 2 SKYLIGHT trial, expected in late 2027 or early 2028. The program is early-stage (SPY007 still preclinical) and represents one of several pipeline programs at Spyre, which has a market cap suggesting the stock is primarily driven by the more advanced IBD assets (SPY001, SPY002, SPY003).
SPY772 has no near-term catalyst; the next meaningful event is the SKYLIGHT Phase 2 topline readout in late 2027 or early 2028. For investors tracking Spyre, the more immediate catalysts are the ongoing SKYLINE Part B combination data (SPY001/SPY002/SPY003 pairwise combinations in IBD) and the company's progress toward pivotal studies. SPY772 is a long-duration option on HS expansion that will not resolve for over a year.
Price Chart
Executive Summary
SPY772 is a preclinical/early Phase 2 combination program from Spyre Therapeutics (NASDAQ: SYRE) that pairs two long-acting antibodies: SPY072 (anti-TL1A) and SPY007 (anti-IL-17A/F) for hidradenitis suppurativa (HS). The program was launched in August 2026 alongside the initiation of the Phase 2 SKYLIGHT surrogate trial. SPY007 has not yet been tested in humans, and topline data from SKYLIGHT is not expected until late 2027 or early 2028. Spyre has a strong cash position (~$1.5B pro forma) and a broad pipeline of IBD and immunology assets, but SPY772 is an early-stage, non-binary program for the foreseeable future. The stock trades near $99 with a strong analyst consensus (21 Buy/Strong Buy) and a mean price target of $122.53, implying ~23% upside.
How It Works
SPY772 is a combination of two engineered antibodies designed to be given together as a single shot. One antibody (SPY072) blocks TL1A, a protein that drives inflammation in the gut and skin. The other (SPY007) blocks IL-17A and IL-17F, two related inflammatory signals. By hitting two different inflammatory pathways at once, the combination aims to deliver stronger and more durable symptom control than blocking either pathway alone, with the convenience of infrequent dosing.
Trial Status
SPY772 was launched in August 2026 as a combination program pairing SPY072 (anti-TL1A, already in Phase 2 for rheumatoid arthritis) with SPY007 (anti-IL-17A/F, still preclinical). The Phase 2 SKYLIGHT trial in hidradenitis suppurativa (HS) began enrolling in August 2026. The trial is a randomized, placebo-controlled proof-of-concept study (n~150) evaluating dual inhibition of TL1A and IL-17A/F. The primary endpoint is the proportion of patients achieving HiSCR75 response at Week 16. The trial design uses SPY072 in patients initiating bimekizumab as a surrogate proof-of-concept for the eventual SPY772 coformulation.
The Two-Sided Case
Upcoming Catalysts
- Topline Week 16 HiSCR75 data from Phase 2 SKYLIGHT trial expected late 2027 or early 2028
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report